Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal
pharmafile | July 14, 2020 | News story | Manufacturing and Production, Research and Development | Blueprint Medicines, Cancer, Roche, pralsetinib
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib as a treatment of cancer driven by oncogenic RET alterations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers and solid tumours.
The deal is the latest agreement between the two companies, which have been working together since 2016.
As part of the deal, Roche will pay $775 million to Blueprint up front, comprising $675 million in cash and a $100 million equity investment. Roche will share co-exclusive rights with Blueprint to market pralsetinib in the US, and will also pick up exclusive rights to the product everywhere else in the world except in Greater China.
Jeff Albers, Chief Executive Officer of Blueprint Medicines, commented on the deal: “This collaboration will accelerate our ability to bring pralsetinib to patients with significant medical needs around the world and expand development of pralsetinib across multiple treatment settings where there is potential to benefit even broader patient populations.”
Roche will also have the option to opt in to one additional RET compound developed together with Blueprint under the partnership, with the latter eligible to receive up to $927 million in development, regulatory and sales milestone payments off the back of either pralsetinib or the additional RET compound. On top of this, Blueprint is also eligible for tiered royalty payments on sales of these therapies outside of the US.
Matt Fellows
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
